



Noxopharm extends strategic partnership with Hudson Institute of Medical Research

Highlights

- **Strategic partnership extended for a further 12 months**
- **Broader range of promising proprietary assets**
- **Growing market for RNA-related technologies**

Sydney, 13 February 2024: Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce that it has renewed its strategic partnership with Melbourne's Hudson Institute of Medical Research for a further 12 months.

The partnership and in-licensed technology are key components of the company's Sofra™ platform, via which Noxopharm is building a promising portfolio of assets including the SOF-VAC™ mRNA vaccine enhancer and SOF-SKN™ topical skin medication for lupus and psoriasis.

Hudson Institute is a leading Australian medical research organisation recognised internationally for discovery science and translational research, and home to Australia's largest group of inflammation and immunity scientists and clinicians. Among them is Associate Professor Michael Gantier, an expert in nucleic acids biology whose research is opening novel therapeutic avenues to dampen the inflammation that leads to autoimmune diseases.

The updated contract will see Noxopharm, A/Prof Gantier and the Hudson Institute team continue to develop the Sofra platform while increasing the company's asset library. This will involve focusing not only on important inflammatory receptors like TL7 and TLR8, but also broadening the range of proprietary oligonucleotides that can be used to turn various other inflammatory receptors on or off as required.

Hudson Institute Director and CEO Professor Elizabeth Hartland said: "We are very pleased to be broadening and deepening our relationship with Noxopharm, especially at a time when interest in RNA-related technologies is higher than it has ever been. We strongly believe in long-term partnerships with trusted commercial partners like Noxopharm and are looking forward to seeing our work together develop as the year progresses."

Noxopharm CEO Dr Gisela Mautner said: "In conjunction with the Hudson Institute team, we are making significant progress with our Sofra platform and advancing towards our goal of establishing Noxopharm as a leader in Australia in the RNA space. The commercial opportunities for us are considerable because the RNA market is expanding rapidly and will be sizeable in the future, and our ongoing strategic partnership is therefore a critical aspect of building shareholder value."



As part of current initiatives to promote Sofra's proprietary technology to key international audiences, Dr Mautner will be speaking at the RNA Leaders Europe Conference in Switzerland in March.

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US biotech company Nyrada Inc (ASX:NYR), which focuses on drug development for cardiovascular and neurological diseases.

To learn more, please visit: noxopharm.com

About Hudson Institute of Medical Research

A global bioscience medical research leader, Hudson Institute's sole focus is on powering breakthrough scientific discoveries into improved health care that will transform lives. We strive to improve human health through ground-breaking, collaborative medical research discoveries and their translation to real world impact. Hudson Institute scientists research five areas of medical need:

- Inflammation
- Reproductive health and pregnancy
- Infant and child health
- Cancer
- Hormones and health

To learn more, please visit: www.hudson.org.au

Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com

Company Secretary:

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Hudson Institute Media enquiries:

Rob Clancy

Communications & Media Manager

M: + 61 408 579 313



E: rob.clancy@hudson.org.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.